0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FMC63

FMC63

Product ListCompare or Buy

Part of Bioactivity data

FM3-BY54-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) Biotinylated Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1, Avitag (Cat. No. FM3-BY54) and isotype control respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

FM3-HPY53-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

1e6 of the Anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 (Cat. No. FM3-HPY53) and negative control antibody respectively, PE signal was used to evaluate the binding activity (QC tested).

FM3-S93-MALS-HPLC
Rabbit Anti-Mouse FMC63 scFv Polyclonal Antibody (Cat. No. ) MALS images

The purity of Rabbit Anti-Mouse FMC63 scFv Polyclonal Antibody (Cat. No. FM3-S93) was more than 90% and the molecular weight of this protein is around 130-145 kDa verified by SEC-MALS.

Bioactivity-ELISA
Rabbit Anti-Mouse FMC63 scFv Polyclonal AntibodyRabbit Anti-Mouse FMC63 scFv Polyclonal Antibody (Cat. No. FM3-S93) ELISA bioactivity

Immobilized FMC63 scFv at 2 μg/mL (100 μL/well) can bind Rabbit Anti-Mouse FMC63 scFv Polyclonal Antibody (Cat. No. FM3-S93) with a linear range of 0.098-0.78 ng/mL (QC tested).

FM3-S93-ELISA
Rabbit Anti-Mouse FMC63 scFv Polyclonal AntibodyRabbit Anti-Mouse FMC63 scFv Polyclonal Antibody (Cat. No. FM3-S93) ELISA bioactivity

Immobilized FMC63 scFv at 2 μg/mL (100 μL/well) can bind Rabbit Anti-Mouse FMC63 scFv Polyclonal Antibody (Cat. No. FM3-S93) with a linear range of 0.098-0.78 ng/mL (QC tested).

Customer Reviews

Synonym Name

Anti-FMC63 Ab & Anti-FMC63 scFv Antibody

Background

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

Clinical and Translational Updates

    This web search service is supported by Google Inc.

    totop